Abstract：【Objective】 To investigate the application value of anti angiogenesis drugs combined with paclitaxel and cisplatin in non-small cell lung cancer(NSCLC).【Methods】A total of 80 patients with NSCLC in our hospital were selected and divided into control group(n=40, paclitaxel and cisplatin chemotherapy) and observation group(n=40, bevacizumab combined with paclitaxel and cisplatin chemotherapy) according to different treatment schemes. The clinical effective rate, changes of tumor markers and immune indexes, quality of life and adverse reactions of the two groups were compared. 【Results】The total effective rate of the observation group was 57.5%(23/40), which was higher than 25.00%(10/40) of the control group, and there was significant difference between the two groups(P<0.05); Carcinoembryonic antigen, vascular endothelial growth factor(VEGF) and basic fibroblast growth factor(bFGF) of the two groups were improved after treatment(P<0.05), and the observation group was better than the control group(P<0.05); After treatment, the levels of CD3+ CD4+ CD8+ CD4+/CD8+ in the observation group were higher than those before treatment(P<0.05); The levels of CD3+ CD4+ CD8+ in the control group were lower than those before treatment(P<0.05), and the indexes in the observation group were higher than those in the control group(P<0.05); The quality of life score of the observation group was(46. 81±7. 58) was higher than(38. 17 ±7. 29)(P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). 【Conclusion】 Anti angiogenic drugs combined with paclitaxel and cisplatin in the treatment of NSCLC has higher clinical efficacy and fewer adverse reactions, which can effectively improve the immune system damage, promote the recovery of tumor markers and improve the quality of life of patients.
2021, Vol. 38 
